More News of Interest

Defymed Accelerates Its Development in the United States

September 20, 2019

Defymed, which specializes in the design and development of innovative medical devices for the delivery of therapeutic treatments, will be exploring business and scientific opportunities in Boston this September 25 to October 5 as part of the Innouvo program.

Defymed, since June of 2019, and 4 other Strasbourg start-ups from the health sector have benefitted from the intensive support provided by the program to expand their presence in the US market. This program will allow Defymed to support its international expansion by developing new partnerships in the United States.

The company is currently developing two medical devices for the physiological treatment of diabetes and other chronic diseases. ExOlin®, an insulin delivery medical device, should offer patients better management of their disease and improve their quality of life while allowing them to continue their normal activities. MailPan®, a bioartificial pancreas containing insulin-secreting cells, should allow the physiological and autonomous treatment of diabetes while maintaining better glycemic stability for patients.

The company is currently carrying out a fundraising round to finance clinical tests for ExOlin® in Europe starting early 2020, needed for its future market approval. In addition, thanks to the Innouvo program, Defymed will be able to accelerate and pursue its expansion into the United States. Its visit to Boston with the Strasbourg delegation, from September 25 to October 5, will allow the company to form new strategic partnerships needed for the future clinical development of its innovative medical devices in the United States. Defymed’s spearhead is to offer patients with better disease management and therefore, a better quality of life.

Séverine Sigrist CEO of Defymed, said “The Innouvo program is a real growth opportunity for Defymed. The United States, and Boston in particular, are a strategic place where we need to strengthen our presence. Alistair Schneider and his team have boosted our confidence and given us the keys to be present on the US market. The business and scientific meetings organized during our visit will help us accelerate the development of ExOlin® and MailPan® devices. Exporting our solutions to the United States is expected to widen our applications towards patients!”

Latest Posts

spot_img

Don't Miss

Stay on top - Get Medical Device News Magazine daily news in your inbox

Enter your email address:

Delivered by FeedBurner